Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled “Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes,” will be presented at the author Q&A session scheduled for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT.

“This study was conducted in vitro using model biological membranes under conditions of hypercholesterolemia,” commentedPreston Mason, Ph.D., of Brigham and Women’s Hospital and the study’s lead investigator. “The purpose of the study was to examine whether EPA, under atherosclerotic-like conditions, can reduce the formation of cholesterol crystalline domains. Our research team found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65% (p< 0.05) as compared to vehicle-treated (ethanol) controls.”

Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body.

This poster will be presented by Dr. R. Preston Mason, PhD, of Brigham and Women’s Hospital. Dr. Mason is also the President and Founder of Elucida Research. (Original Source)

Shares of Amarin Corporation closed yesterday at $2.33 . AMRN has a 1-year high of $3.33 and a 1-year low of $0.78. The stock’s 50-day moving average is $2.10 and its 200-day moving average is $1.68.

On the ratings front, Amarin Corporation has been the subject of a number of recent research reports. In a report issued on March 12, H.C. Wainwright analyst Andrew Fein upgraded AMRN to Buy, with a price target of $10, which represents a potential upside of 329.2% from where the stock is currently trading. Separately, on March 3, Oppenheimer’s Akiva Felt reiterated a Hold rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Fein and Akiva Felt have a total average return of 26.0% and 35.7% respectively. Fein has a success rate of 66.7% and is ranked #112 out of 3621 analysts, while Felt has a success rate of 68.8% and is ranked #25.

Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.